An issue of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) bonds fell 0.9% against their face value during trading on Monday. The debt issue has a 3.65% coupon and is set to mature on November 10, 2021. The debt is now trading at $95.88 and was trading at $96.50 last week. Price changes in a company’s bonds in credit markets sometimes anticipate parallel changes in its share price.
Several equities analysts have commented on the company. Cantor Fitzgerald set a $25.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, July 13th. Royal Bank of Canada reissued a “hold” rating and set a $19.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Tuesday, July 31st. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 2nd. Morgan Stanley raised their price objective on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 3rd. Finally, Credit Suisse Group set a $26.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, September 17th. Five analysts have rated the stock with a sell rating, sixteen have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus price target of $21.68.
Shares of TEVA traded down $0.20 during trading hours on Monday, hitting $21.23. The company had a trading volume of 8,302,949 shares, compared to its average volume of 12,813,170. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.03 and a quick ratio of 0.69. The firm has a market cap of $21.79 billion, a PE ratio of 5.40, a P/E/G ratio of 1.77 and a beta of 0.71. Teva Pharmaceutical Industries Ltd has a 52-week low of $10.85 and a 52-week high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. The firm had revenue of $4.70 billion during the quarter, compared to analyst estimates of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. Teva Pharmaceutical Industries’s quarterly revenue was down 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.02 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.69 EPS for the current year.
In other news, VP Richard Daniell sold 2,488 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Deborah A. Griffin sold 2,376 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the transaction, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,350 shares of company stock valued at $239,430. 0.43% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of the business. IFM Investors Pty Ltd raised its position in Teva Pharmaceutical Industries by 15.8% in the 3rd quarter. IFM Investors Pty Ltd now owns 50,123 shares of the company’s stock worth $1,080,000 after buying an additional 6,823 shares during the last quarter. Managed Account Services Inc. purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $234,000. Strs Ohio raised its position in Teva Pharmaceutical Industries by 47.0% in the 3rd quarter. Strs Ohio now owns 1,259,943 shares of the company’s stock worth $27,139,000 after buying an additional 402,800 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $509,000. Finally, Nisa Investment Advisors LLC raised its position in Teva Pharmaceutical Industries by 6,144.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 23,293 shares of the company’s stock worth $504,000 after buying an additional 22,920 shares during the last quarter. 64.69% of the stock is owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries (NYSE:TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.